Two companies streamline product portfolios
One major pharmaceutical company unloaded a bevy of over-the-counter products at press time as another announced its plan to sell its entire line of prescription generics.
One major pharmaceutical company unloaded a bevy of over-the-counter products at press time as another announced its plan to sell its entire line of prescription generics.
Novartis Consumer Health Inc., Summit, NJ, sold 14 over-the-counter brands to Heritage Consumer Products L.L.C., Brookfield, CT, for $20 million.
Meanwhile, Hoescht Marion Roussel, Kansas City, MO, told shareholders it would sell its generic pharmaceutical subsidiary, The Rugby Group, Norcross, GA.
Included in Novartis's sale were the cold and allergy products Allerest, Nostrilla, Privine, Sinarest and Vitron; the topical products Americaine, Caldecort, Caldesene, Eucalyptamint and Ting; the gastrointestinal products Bacid, Fiberall and Kondremul and the diet product Acutrim.
The Federal Trade Commission has approved the sale.
Novartis decided to sell the brands after a product rationalization study indicated that their sales were necessary in order for the company to focus on its leading over-the-counter brands. Novartis will continue to market its successful products Ascriptin, Desenex, Doan's, Ex-Lax, Gas-X, Habitrol, Maalox, Tavist-D, Theraflu and Triaminic.
In its most recent shareholder's report, Hoescht Marion Roussel cited a 17% decline in sales of generics in the first half of the year and a grim outlook for market improvement as reasons for its decision to sell.
The company also emphasized its conviction that it should concentrate its pharmaceutical efforts on innovative new products rather than on cheaper versions of existing ones.
Watson Pharmaceuticals, Corona, CA, stepped forward to take Hoescht Marion Roussel up on its offer. Although full financial details were not disclosed, the agreement includes an initial payment of $70 million, contingent payments on certain products and an upside-sharing payment based on certain future operating results.
The acquisition will enable Watson to nearly double its manufactured generic products and expand its new product pipeline by six additional Abbreviated New Drug Applications. PR
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
